TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Oral Health Educational Methods in Adolescence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adolescents of both sexes~* Regularly enrolled in the high school of a public institution~Exclusion Criteria:~* Participants with physical or mental condition~* Absence of signing consent form~* Adolescents with fixed orthodontic apparatus

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- Oral orientation and App for smartphone (Type: EXPERIMENTAL): The oral health educational method of this group comprised a total of 66 adolescents aged between 14 and 19 years who received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases. The participants of this group also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
- Oral orientation (Type: EXPERIMENTAL): The oral health educational method of this group comprised a total of 71 adolescents aged between 14 and 19 years who received standardized oral guidance performed by one of the previously trained researchers and included aspects of general and oral health and, in particular, of periodontal diseases.
- Video orientation and App for smartphone (Type: EXPERIMENTAL): The oral health educational method of this group comprised a total of 63 adolescentes aged between 14 and 19 years who received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience. The participants of this group also received an App for smartphone containing messages of reinforcement in oral health which was sent during a period of 30 days.
- Video orientation (Type: EXPERIMENTAL): The oral health educational method of this group comprised a total of 63 adolescentes aged between 14 and 19 years who received oral health information through an audiovisual material produced especially to this research to offer a teaching medium capable of arousing the attention of its audience.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Japanese Treat and Extend Study of Aflibercept in Neovascular Age-related Macular Degeneration

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Japanese men and women ≥ 50 years of age~* Active primary subfoveal choroidal neovascularization (CNV) lesions secondary to wAMD, including juxta-foveal lesions that affect the fovea as evidenced by fluorescein angiography (FA) in the study eye~* Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) of 73 to 25 letters (approximately 20/40 to 20/320 at Snellen equivalent) in the study eye~Exclusion Criteria:~* Prior treatment of the study eye with intraocular anti-VEGF(Vascular Endothelial Growth Factor) agents, verteporfin photodynamic therapy (PDT), other laser, intraocular corticosteroids, surgical interventions (except cataract surgery more than 30 days prior to screening) or systemic use of anti-VEGF products within 3 months prior to study entry~* Active or suspected infection in or surrounding of the study eye~* Active severe intraocular inflammation in the study eye~* Intraocular pressure (IOP) ≥ 25 mmHg in the study eye~* Ocular condition in the study eye which may impact vision and confound study outcomes

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 2 Weeks adjustment (Type: EXPERIMENTAL): Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals with the criteria of Treat and Extend regimen. In the case the study eye of a participant met the criteria, the length of treatment interval was to be extended or shortened by 2 weeks from the last interval, respectively. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96.
- 4 Weeks adjustment (Type: EXPERIMENTAL): Participants received Aflibercept IVT injection at Week 0, Week 4, Week 8 and Week 16 followed by the variable treatment intervals. In the case the study eye of a participant met the criteria of the shortening, the length of the treatment interval was to be shortened by 2 weeks. But when the last treatment interval for a participant was extended by 4 weeks from the second last interval, the treatment interval was shortened by 4 weeks. In the case the study eye of a participant met the criteria of the extension, the length of the treatment interval was to be extended by 4 weeks. But when a participant had a history of receiving treatment with interval shortened by 4 weeks during this study, the length of the extension was 2 weeks. Minimum/Maximum treatment interval is 8 weeks and 16 weeks during Week 16 to 96.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Self or Clinic Administration of DepoProvera

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. age greater than or equal to 18 years~2. seeking DMPA for contraception~3. English or Spanish speaking~4. consistent access to a working telephone~5. availability for follow up for one year~Exclusion Criteria:~1. suspected or continuing pregnancy~2. undiagnosed vaginal bleeding~3. known or suspected breast cancer~4. acute liver disease~5. known hypersensitivity to medroxyprogesterone acetate or any other components of DMPA~6. desire for pregnancy within one year

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Self Administration of DMPA (Type: EXPERIMENTAL): Self administration of subcutaneous depot medroxyprogesterone acetate
- Clinic administration of DMPA (Type: ACTIVE_COMPARATOR): Clinic administration (routine care) of DMPA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Indian POLYCAP Study (TIPS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 9.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 45 and 80 years~* At least any one of the following CVD risk factors:~  * Stable type 2 diabetes mellitus or~ * Hypertension or~ * Current smoker or~ * A waist to hip ratio \> 0.85 for women and \>0.9 for men or~ * Elevated lipids.~* Informed consent.~Exclusion Criteria:~* On any of the study medications,~* Uncontrolled blood pressure,~* Symptomatic hypotension,~* Any clear indication or a contraindication to the use of any of the study medications,~* History of coronary/cerebrovascular events,~* Pregnancy or lactating or women of child-bearing potential with inadequate contraception and / or an inability to attend follow up visits.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1, POLYCAP (Type: EXPERIMENTAL): Combination of 3 anti hypertensives, lipid lowering agent and anti platelet agent
- 2 B (Type: ACTIVE_COMPARATOR): Diuretic antihypertensive
- 3 C (Type: ACTIVE_COMPARATOR): Thiazide plus Angiotensis converting enzyme inhibitor - combination antihypertensive.
- 4 D (Type: ACTIVE_COMPARATOR): Diuretic with Beta blocker combination antihypertensive
- 5, E (Type: ACTIVE_COMPARATOR): ACE inhibitor plus Beta blocker combination antihypertensive
- 6, F (Type: ACTIVE_COMPARATOR): Combination antihypertensive of ACE inhibitor, diuretic and beta blocker
- 7,G (Type: ACTIVE_COMPARATOR): Combination of ACE inhibitor, betablocker, diuretic and Antiplatelet
- 8,H (Type: ACTIVE_COMPARATOR): Lipid lowering agent
- 9,A (Type: ACTIVE_COMPARATOR): Antiplatelet

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~* Premenopausal woman at screening.~* Body Mass Index ≥ 18 kg/m2.~* Menstrual cycles ≥ 21 days and ≤ 40 days.~* Presence of uterine fibroids.~* Heavy menstrual blood loss for each of the 2 menstrual periods assessed at screening using the alkaline hematin method.~Key Exclusion Criteria:~* The subject is pregnant or breast-feeding or is planning a pregnancy within the duration of the treatment period of the study.~* History of uterus surgery that would interfere with the study.~* The subject's condition is so severe that she will require surgery within 6 months regardless of the treatment provided.~* Undiagnosed abnormal uterine bleeding.~* Significant risk of osteoporosis or history of, or known osteoporosis or other metabolic bone disease.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OBE2109 dose 1 (100mg) + Placebo Add-back (Type: EXPERIMENTAL): None
- OBE2109 dose 1 (100mg) + Add-back (Type: EXPERIMENTAL): None
- OBE2109 dose 2 (200mg) + Placebo Add-back / OBE2109 dose 2 (200 mg) + Add-back (Type: EXPERIMENTAL): None
- OBE2109 dose 2 (200mg) + Add-back (Type: EXPERIMENTAL): None
- Placebo + Placebo Add-back / OBE2109 dose 3 (200mg) + Add-back (Type: PLACEBO_COMPARATOR): At W24, half of the patients switched to active treatment, while half remained on Placebo; the switch was defined at randomization.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients 18-74 years of age~* Single primary liver transplant from a deceased donor~* CellCept plus tacrolimus or cyclosporine from time of transplantation (within 72 hours)~* Patients with hepatitis C-positive status may be entered if they have had an intraoperative (back table) biopsy of the transplanted liver or will have a biopsy at the time of randomization. This is not required for patients negative for hepatitis C.~Exclusion Criteria:~* Liver allograft from a living donor or a split liver~* Multiple organ transplant~* Dialysis therapy for \>14 days from transplantation to randomization~* History of malignancy in the last 5 years (except hepatoma or non-melanoma skin cancer)~* Previous sirolimus therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- CellCept + CNI (tacrolimus or cyclosporine) (Type: EXPERIMENTAL): None
- CellCept + sirolimus (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Veterans Integrated Service Network (VISN) 23 Lung Disease Self Management/Case Management Program

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~One or more of the following:~* Hospital admission for COPD within the prior year~* Unscheduled visit for COPD within the prior year~* Home oxygen use for COPD~* Systemic steroid use for COPD within the prior year~* Post bronchodilator FEV1 \< 70% predicted~* Post bronchodilator FEV1/FVC \< 70% predicted~Exclusion Criteria:~* Any unstable medical condition that would preclude effective participation in the study, or which would be expected to reduce life expectancy to \< 1 year~* Inability to contact patient by telephone

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): CAse/self management for COPD
- 2 (Type: OTHER): usual care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males or female patients ≥ 55 years of age~* LVH as confirmed by echocardiogram~* Patients with high risk hypertension, currently treated or already taking antihypertensive medication~Exclusion Criteria:~* Renal artery stenosis~* Symptomatic heart failure or known ejection fraction \< 40%~* Myocardial infarction or stroke within 6 months~* Presence of cranial aneurysm clips, coronary artery metal stents and pacemakers~* Pregnant or lactating females~* Cancer within the last 5 years

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Has type 2 diabetes treated with either: \*A stable regimen of metformin for a minimum of 3 months, and/or \*Diet modification and exercise for a minimum of 3 months.~* Has HbA1c of 7.1% to 11.0%, inclusive.~* Has a body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive.~Exclusion Criteria:~* Received any investigational drug within 3 months prior to screening.~* Is currently treated with any of the following excluded medications: \*Thiazolidinediones within 3 months of screening; \* Sulfonylureas within 3 months of screening; \* Insulin within 1 year of screening.~* Participated previously in an exenatide clinical study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group A1 (Type: PLACEBO_COMPARATOR): Placebo lead-in followed by placebo equivalent volume to 0.8 mg exenatide LAR
- Group A2 (Type: PLACEBO_COMPARATOR): Placebo lead-in followed by placebo equivalent volume to 2.0 mg exenatide LAR
- Group B (Type: EXPERIMENTAL): Exenatide lead-in followed by exenatide LAR 0.8 mg weekly
- Group C (Type: EXPERIMENTAL): Exenatide lead-in followed by exenatide LAR 2.0 mg weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven triple-receptor-negative metastatic or relapsed breast cancer~* Minimum interval of 6 months after the end of any previous taxane- containing chemotherapy regimen~* At least one tumor lesion measurable according to RECIST criteria~* Gender: female~* Age \>= 18 years old~* Negative pregnancy test (females of childbearing potential)~* Willingness to perform double-barrier-contraception during study and for 6 months post chemotherapy treatment~* ECOG performance status 0, 1 or 2~* Signed informed consent~Exclusion Criteria:~* More than 1 previous chemotherapeutic treatment for metastatic or relapsed disease~* Major surgery \< 4 weeks prior to enrollment~* Immunotherapy \< 2 weeks prior to enrollment~* Severe pulmonary obstructive or restrictive disease~* Uncontrolled inflammatory disease (autoimmune or infectious)~* Clinically significant cardiac disease (NYHA stadium \> 2)~* Laboratory tests (hematology, chemistry) outside specified limits~* Pregnancy or nursing status~* Known positive HIV testing~* Known hypersensitivity to any component of the EndoTAG-1 or taxane formulations~* History of malignancy other than breast cancer \< 5 years prior to enrollment, except skin cancer (i.e. basal or squamous cell carcinoma) treated locally~* Known progressive cerebral metastasis (patients with cerebral metastases in a stable state or after successful surgical or radiological treatment are allowed to participate in the study)~* History of active or significant neurological disorder or psychiatric disorder that would prohibit the understanding and giving of informed consent, or would interfere in the clinical and radiological evaluation of central nervous system during the trial~* Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): EndoTAG-1 + Paclitaxel
- 2 (Type: EXPERIMENTAL): EndoTAG-1
- 3 (Type: ACTIVE_COMPARATOR): Paclitaxel

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Outpatients~* Sexually active women participating in the study must use a medically acceptable form of contraception~* Subjects must have a primary diagnosis of major depressive disorder~Exclusion Criteria:~* Treatment with DVS-233 SR at any time in the past~* Treatment with venlafaxine (immediate release \[IR\] or extended release \[ER\]) within 90 days of study day 1~* Known hypersensitivity to venlafaxine (IR or ER)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Premenopausal women 18 to 49 years of age are eligible for enrollment~* Patients have operable stage I to IIIA breast cancer for which treatment with adjuvant or neoadjuvant cyclophosphamide-containing chemotherapy was planned.~* Eligible participants had taken no estrogens, antiestrogens, selective estrogen-receptor modulators, aromatase inhibitors, or hormonal contraceptives within the month before enrollment.~* Human chorionic gonadotropin negative by urine test before entering the group.~* Informed consent, understanding and compliance with the requirements of the study.~* No significant chronic disease and any organ dysfunction.~Exclusion Criteria:~* Exceptions were made for the use of hormonal contraception in women younger than 35 years of age that was discontinued before randomization.~* Use of hormonal treatment for up to 2 months for the purposes of in vitro fertilization and cryopreservation of embryos or oocytes before randomization.~* Patients with metastatic lesions or history of bilateral ovariectomy,ovarian radiation were excluded.~* Patients received previous adjuvant endocrine therapy for breast cancer are not suitable to this trial.~* Patients with uterine and/or adnexal diseases needing medical or surgical treatment are not suitable.~* Allergic to active or inactive excipients of GnRHa is an exclusion criterion.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- GnRHa group (Type: EXPERIMENTAL): Eligible patients with breast cancer treated with GnRHa while receiving chemotherapy.
- None GnRHa group (Type: NO_INTERVENTION): Eligible patients with breast cancer treated without GnRHa while receiving chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete